徳島大学 教育・研究者情報データベース(EDB)

1. 後東 久嗣

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 埴淵 昌毅([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域呼吸器・血液・代謝内科学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Sakaguchi Satoshi

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Kanematsu Takanori

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 柿内 聡司

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. (英) Tomimoto Hideki

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Azuma Masahiko

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. 手塚 敏史

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Tada Hiroya

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Miki Yukiyo

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. (英) Nakamura Toshimi

    役割	任意
    貢献度	任意
    学籍番号	推奨

12. 曽根 三郎

    役割	任意
    貢献度	任意
    学籍番号	推奨

13. 西岡 安彦([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.呼吸器・膠原病内科学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital.

(英) Platinum-doublet regimens and docetaxel as first- and second-line chemotherapy, respectively, are shown to prolong the survival of lung cancer patients in various randomized phase III studies. However, the evidence for the efficacy of chemotherapy for lung cancer in the clinical practice is still insufficient. In the present study, we investigated the effectiveness and safety of outpatient chemotherapy for lung cancer in the clinical practice. Ninety-four lung cancer cases were retrospectively analyzed. Among these cases, 67 (71.3%) were non-small cell lung cancer (NSCLC) and 27 (28.7%) were small cell lung cancer (SCLC). The response rates in SCLC and NSCLC patients were 55.6% (15/27) and 16.9% (11/65), respectively. Objective tumor response rates for the patients were found to decrease substantially with each line of treatment as described previously. All adverse events were well tolerated and no treatment-related death was observed. Median time to treatment failures (TTFs) of first-line treatment were 10.1 months and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured by the appropriate therapeutic management.

1. (英) Adult
2. (英) Aged
3. (英) Aged, 80 and over
4. (英) Antineoplastic Agents
5. (英) Carcinoma, Non-Small-Cell Lung
6. (英) Carcinoma, Small Cell
7. (英) Female
8. (英) Hospitals, University
9. (英) Humans
10. (英) Lung Neoplasms
11. (英) Male
12. (英) Middle Aged
13. (英) Outpatients
14. (英) Retrospective Studies

1. (英) Article.Affiliation: Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.

2. (英) Article.PublicationTypeList.PublicationType: Journal Article